N/A
Completed N=52
Treatment of Unresectable Colorectal Metastases by Radiofrequency Ablation Combined or Not With Resection, With or Without Neoadjuvant Chemotherapy.
Source: ClinicalTrials.gov NCT00210106 ↗Enrolled (actual)
52
Serious AEs
10.2%
Results posted
May 2021
Primary outcomePrimary: Complete Hepatic Response Rate at 3 Months — 79 percentage of participants
Summary
The hypothesis is that radiofrequency ablation combined or not with resection may allow a local control (the liver) in patients suffering from unresectable colorectal liver metastases. Patients may have benefit or not from a preoperative (neoadjuvant) chemotherapy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Complete Hepatic Response Rate at 3 Months |
79 | — |
| SECONDARY Overall Survival |
97.4; 91.7 | — |
| SECONDARY Event-free Survival |
18.4; 10.5 | — |
Eligibility Criteria
Inclusion Criteria
Colorectal cancer Hepatic metastases unresectable by classical surgery Performance status < 2
Exclusion Criteria
-
Data sourced from ClinicalTrials.gov (NCT00210106). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.